Actively Recruiting

All Genders
NCT07045571

MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer

Led by Yingbin Liu, MD, PhD, FACS · Updated on 2025-07-01

1000

Participants Needed

1

Research Sites

194 weeks

Total Duration

On this page

Sponsors

Y

Yingbin Liu, MD, PhD, FACS

Lead Sponsor

X

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Collaborating Sponsor

AI-Summary

What this Trial Is About

Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.

CONDITIONS

Official Title

MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 80 years old
  • Pancreatic space-occupying lesion identified by imaging with high suspicion of pancreatic malignant tumor and planned surgery or biopsy
  • At least one measurable lesion with longest diameter ≥10mm on spiral CT scan according to RECIST 1.1 criteria
  • Ability to provide tumor tissue and blood samples
  • Stable vital signs with ECOG score of 0-1
  • Liver function with AST and ALT ≤ 5 times upper limit of normal, Child-Pugh class A or B
  • White blood cell count > 3x10^9/L, absolute neutrophil count ≥ 1.5x10^9/L
  • Platelets ≥ 75x10^9/L
  • Hemoglobin ≥ 90g/L
  • Creatinine clearance rate ≥ 60ml/min
  • Total bilirubin ≤ 3 times upper limit of normal
  • Patients of reproductive age and their spouses willing to use contraception
  • Female patients must have a negative pregnancy test within 7 days before enrollment
  • Voluntary participation with good compliance; legal representative consent if participant unable to consent
Not Eligible

You will not qualify if you...

  • Unable to provide tumor tissue and blood samples
  • Prior molecular targeted therapy, immunotherapy, or anti-tumor radiochemotherapy before this study
  • History of malignancies other than pancreatic cancer
  • Severe diseases such as uncontrolled congestive heart failure (NYHA III or IV), unstable angina, poorly controlled arrhythmias, uncontrolled moderate to severe hypertension (SBP > 160mmHg or DBP > 100mmHg)
  • Uncontrolled diabetes
  • Active infection
  • Active autoimmune diseases requiring long-term steroids
  • History of allogeneic transplantation
  • Active psychiatric disorders affecting consent or protocol compliance
  • Other severe illnesses deemed inappropriate by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Renji hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Actively Recruiting

Loading map...

Research Team

Y

Yinbin Liu, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here